Significant Progress in CAR T-Cell Therapy for Difficult-to-Treat Hematologic Malignancies

Details

Ressource 1Download: 55658-significant-progress-in-car-t-cell-therapy-for-difficult-to-treat-hematologic-malignancies.pdf (975.49 [Ko])
State: Public
Version: Final published version
License: CC BY-NC-SA 4.0
Serval ID
serval:BIB_99272140464E
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
UNIL/CHUV
Title
Significant Progress in CAR T-Cell Therapy for Difficult-to-Treat Hematologic Malignancies
Journal
healthbook TIMES Oncology Hematology - Edition 3 / 2022
Author(s)
Stadelmann Raphael, Cairoli Anne, Arber Caroline
ISSN
2673-2106
2673-2092
Publication state
Published
Issued date
31/10/2022
Peer-reviewed
Oui
Number
13
Language
english
Abstract
The latest clinical and real-world evidence of chimeric antigen receptor (CAR) T-cell therapy continues to challenge standard
treatment paradigms for many hematologic malignancies with limited treatment options. In particular, recently approved CAR
T-cell therapies are forging a path towards improving patient outcomes and health-related quality of life (HRQoL) in difficultto-
treat relapsed/refractory (R/R) blood cancers such as diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM),
mantle cell lymphoma (MCL) and B-cell acute lymphoblastic leukemia (B-ALL). Here the latest data on commercially available
CAR T-cell therapies are summarized and discussed.
Keywords
Oncology, Hematology
URN
urn:nbn:ch:serval-BIB_99272140464E9
OAI-PMH
oai:serval.unil.ch:BIB_99272140464E
DOI
10.36000/hbt.oh.2022.13.085
Open Access
Yes
Create date
17/08/2023 13:17
Last modification date
18/08/2023 7:13
Usage data